

Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences

Treatment of Lung Cancer by Targeted Drug Delivery Systems

Venkateswarlu N

Department of Pharmacy, Vagdevi College of Pharmacy, Nellore, Andhra Pradesh-542001, India

Short Communication

Received: 19/02/2014

Revised: 28/03/2014

Accepted: 03/03/2014

*For Correspondence

Department of Pharmacy,
Vagdevi College of Pharmacy,
Nellore, Andhra Pradesh-
542001, India, Mobile: +91
9000187511, E-mail:
nussum.venkatesh@gmail.com

Keywords: Carcinoma, Liposome,
nanoparticles, tumour

ABSTRACT

In the gift state of affairs, carcinoma is one in every of the foremost rife and malignant cancer particularly among the smoking cluster of individuals. The targeted delivery of therapy agents to the lungs represents a completely unique therapeutic approach in carcinoma. Respiratory organ is a perfect route for administration of metastatic tumour drug because it provides larger alveolar extent, low thickness of animal tissue barrier & in depth biological process. Nanoparticles with Nano carriers have risk of cell-targeted drug delivery with lowest general facet impact and toxicity. Pulmonic somatic cell, enzymes, receptors and genes square measure the target of the targeted drug delivery in carcinoma.

INTRODUCTION

Lung cancer is that the most chronic sickness among the all different airways and respiratory organ sickness and one in every of the leading explanation for death worldwide [1-4]. Carcinoma is common in each men and ladies having exposure to each direct and indirect smoking cluster. In 1975 the 5-year relative survival rate for all patients with carcinoma was thirteen. In 1996 to 2003 the 5-year survival rate magnified to Sixteen Personality Factor Questionnaire despite the incorporation of recent therapy regimens and nice advances in supportive care. And in recent 5-year survival rate for all patients with carcinoma is 15 August 1945. The speedy changes in life vogue, urbanization, and environmental degradation, smoking habit, increasing old population in developed countries etc., square measure all causative toward the rise in patients with airway diseases. Pulmonic diseases square measure treated by maintaining high and prolonged drug concentration in lungs either administered by pulmonic route or general route. The long survival rate of carcinoma [5-8] patients treated by standard approaches like surgical surgery, radiation, and therapy remains far away from satisfactory. Carcinoma cells square measure usually classified as small-cell (SCLC) or non-small-cell respiratory organ carcinomas (NSCLC). NSCLC is additional divided into adenocarcinomas (AD), large-cell carcinomas (LC), and epithelial cell carcinomas (SQ). General drug deliveries of antitumour malignant neoplasm metastatic tumor medicine have slender safety vary spectrum as a result of restricted quantity of drug reaches to the target tumor web site. Targeted drug delivery of antitumour malignant neoplasm metastatic tumor drug on tumor web site in lungs improves the therapeutic impact as a result of it decreases the general exposure of drug. Lungs give giant extent (about 100m²) and high biological process that chop-chop distribute the molecules. Lungs exhibit comparatively low native metabolic activity and in contrast to the oral route of drug administration, pulmonic inhalation isn't subject to first-pass metabolism [9-11].

Recently the interest to develop pulmonic drug delivery system appropriate for carcinoma has been magnified. There square measure varied metric linear unit and micrometer-sized drug carrier system has been investigated for the treatment of carcinoma like nanoparticle, compound conjugates, compound micelles, inhalation nanoparticle, Solid macromolecule nanoparticles, macromolecule nanocapsules, compound nanoparticles, Lipid-coated nanoparticles, Nanostructured macromolecule carriers,

Nanocomposite particles, Liposomal drug delivery system, Microparticles, and Inhalation cistron medical care [12-15].

Nanotechnology Utilized In Carcinoma

Nanoparticle technology [16-21] had emerged on the industrial scale once the primary product victimisation NPs, Abraxane, associate injectable suspension of albumen NPs with certain paclitaxel was used for cancer medical care, and have become on the market in 2005. NPs having the property like little particle size, giant extent, and also the capability of adjusting their surface properties have many blessings compared to different delivery systems. Nano-sized carriers don't seem to be used intravenously owing to accumulation within the liver cell that considerably reduces the number of drug that reaches to the growth web site. Therefore, targeted aerosolised NP delivery is employed in lungs which can bypass the presystemic metabolism. Helmut Ringsdorf projected the idea of polymer-drug conjugates in 1975 and also the resulting success of N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-doxorubicin conjugate (named "PK1") in clinical trials. Compound based mostly nanocarriers have smart drug solubilityhigh drug-loading capability, improve therapeutic efficaciousness, and cut back general toxicity. Docetaxel (DTX) could be a cytotoxic agent that has been proved to own important growth activity against varied human cancers. Nowadays, wide researched polymers for Docetaxel (DTX) delivery are investigated embody polythene glycol (PEG), polyglutamic acid (PGA), polylactic-co-glycolic acid (PLGA), HPMA copolymers, and polysaccharides (eg, chitosan, cyclodextrin).

Lipid-Based Nanocarriers

Liposomes [22-25], micelles, and macromolecule nanoparticles [26-30] square measure the main categories of lipid-based nanocarriers for drug delivery system. Liposomes are getting a lot of} more standard delivery vehicles for metastatic tumor medical specialty because of their sturdy biocompatibility properties. Liposomes conjointly function a perishable pulmonic reservoir that enhance pulmonic duration, decrease mucociliary clearance of medication, forestall native irritation, and increase drug efficiency. In 2004, Boulikas developed a liposome-based cisplatin drug known as Lipoplatin to cut back general toxicity of cisplatin [31-33]. Liposomal formulations have long instability as major downside thus; liposomes will be freeze-dried or dry out to boost the steadiness and might be developed as liposomal dry powder for inhalational pulmonic delivery. As per a recent report, lipoplatin is anticipated to finish phase III clinical trial testing in 2013 and 2014.

Polymeric Nanoparticles

Polymeric nanoparticles square measure synthesized from polymers. Currently a days varied perishable polymers are developed like poly (lactic acid)(PLA), poly(lactic-co-glycolic) acid (PLGA), gelatin, albumin, chitosan, polycaprolactone, and poly-alkyl-cyanoacrylates. And theyhave utilized in quality owing to their controlledand sustained unleash properties, subcellular size, and biocompatibility. Compound nanoparticles are extensively used for delivering targeted chemotherapeutics to carcinoma. These nanoparticles incontestible increased cellular uptake in EGFR over expressing neoplastic cell lines holding promise for targeted carcinoma medical care. Recently, Jiang et al. [34-36] investigated totally different compound-based nanoparticles composed of polycaprolactone (PCL) that were surface changed with chitosan polymer for oral administration of therapy [37-40] in carcinoma. Polymers have mucoadhesive properties that magnified the therapeutic impact of metastatic tumor medicine by selection interacting with the magnified levels of glycoprotein [41-43] expressed in cancer cells [44-47] compared to traditional cells.

Metal-Based Nanoparticles

Noble metals like gold and silver are extensively investigated for clinical applications, together with their use in sensitive diagnostic imaging, detecting, and classifying of carcinoma. Peng et al. [5] developed a gold nanoparticle-based biosensor system with the capability to find carcinoma by associatealyzing an individual's exhaled breath.

CONCLUSION

Targeted drug delivery is incredibly helpful because it improves the therapeutic outcome once treated carcinoma. In recent year the event of molecule targeted drug has progressed remarkably and numerous clinical studies are meted out on molecular targeted medicine for cancer treatment. They conjointly give additional safety and extremely efficacious treatment of carcinoma.

REFERENCES

1. Adamowicz K. Combining Systemic Therapies with Radiation in Non-Small Cell Lung Cancer. *J Cancer Sci Ther.* 2015;7:102-110.
2. Najib NM et al. Effect of Replicate Design on Drug Variability and Bioequivalence in Humans. *J Bioanal Biomed.* 2009;1:014-016.
3. Harahap Y et al. Comparative Bioavailability Study of Two Ramipril Tablet Formulations in Indonesian Healthy Volunteers. *J Bioanal Biomed.* 2009;1:017-021.
4. Muralidharan S et al. Bioequivalence Study of Simvastatin. *J Bioanal Biomed.* 2009;1:028-032.
5. Wang N et al. The Bioavailability of Hepatoprotective Flavonoids in Hypericum Japonicum Extract. *J Bioanal Biomed.* 2009;1:033-038.
6. Babu B et al. Pharmacokinetic Evaluation of Metolazone Tablets using healthy Human Volunteers. *J Bioanal Biomed.* 2009;1:039-040.
7. Agabeyoglu I and Incecayir T. Pharmacokinetic Modelling of Lamotrigine from Plasma Concentrations in Healthy Volunteers. *J Bioanal Biomed.* 2009;1:041-045.
8. Ahmad M et al. In-Vitro Release and Pharmacokinetics of Anti-tubercle Drug Ethionamide in Healthy Male Subjects. *J Bioanal Biomed.* 2009;1:046-049.
9. Venkatesh DN et al. Bioavailability Studies on Developed Prochlorperazine Maleate Sustained Release Tablets by HPLC. *J Bioanal Biomed.* 2009;1:054-057.
10. Sushma B and Ravalli R. Recent Developments in Cancer. *J Develop Drugs.* 2015;4:R001.
11. Saida Y et al. Recurrent Interstitial Lung Disease Induced By Various Therapies for Non-Small Cell Lung Cancer. *J Clin Case Rep.* 2014;4:471.
12. Verma A et al. EBUS-TBNA: Are Two Needle Revolutions (Back and Forth Movement of the Needle Inside the Lymph Node) Adequate for Diagnosis of Lung Cancer?. *J Pulm Respir Med.* 2015;5:239.
13. Chung C. Tyrosine Kinase Inhibitors for EGFR Gene Mutation-Positive Non-Small Cell Lung Cancers: An Update for Recent Advances in Therapeutics. *J Pharmacovigilance.* 2015;2:155.
14. Fournel L et al. Thoracic Myelolipoma: A Rare Case of Mistake in Lung Cancer Staging. *J Clin Exp Pathol.* 2014;5:202.
15. Chen YM and Luo YH. Interstitial Lung Disease Induced by Targeted Therapy for Non-Small Cell Lung Cancer: A Review of Diagnosis, Workup, and Management. *J Palliat Care Med.* 2015;5:204.
16. Onuigbo BW. The Visionary Views of Medical Masters of Yester Years on Nature's Norms Point to Present Prospects in the Target Therapy of Cancer. *Biol Med (Aligarh).* 2015;7:221.
17. Karthikeyan S. Resveratrol Modulates Expression of ABC Transporters in Non-Small Lung Cancer Cells: Molecular Docking and Gene Expression Studies. *J Cancer Sci Ther.* 2014;6:497-504.
18. Crvenkova S. Influence of Prognostic Factors on Survival in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Combination of Chemoradiotherapy. *J Nucl Med Radiat Ther.* 2014;5:200.
19. Nobuhiro Kanaji and Nobuki Nanki . Delayed onset, Long-term Efficacy of S-1 Monotherapy for an Elderly Patient with Squamous Cell Lung Cancer. *Chemotherapy.* 2010;4:140.

20. Lee MH et al. Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway. *J Cancer Sci Ther.* 2014;6:468-477.
21. Konno S et al. New Scoring System Available at Home Health Care for Prediction of 14 Days Survival in Lung Cancer Complicated with Lymphangitic Carcinomatosis. *J Palliat Care Med.* 2014;4:200.
22. Liu M et al. Cervical Muscular Metastasis from Squamous Lung Cancer. *Intern Med.* 2014;4:i002.
23. Hanagiri T et al. Indoleamine2,3-Dioxygenase as A Prognostic Factor in Patients with Non-Small Cell Lung Cancer. *J Clin Cell Immunol.* 2014;5:260.
24. Bittner N et al. The EGFR and KRAS Mutation Status and Correlations with the Prevalence of Bone Metastases - The Results of Three Year Retrospective Analysis. *J Carcinog Mutagen.* 2014;5:184.
25. Sung HJ et al. Clinically Applicable Diagnostics Assay Development for Lung Cancer Biomarker, SAA. *J Proteomics Bioinform.* 2014;7:303-309.
26. Parikh R and Jeganathan N. A Short Review: Complementary and Alternative Medicine in Lung Cancer. *J Anc Dis Prev Rem.* 2014;2:115.
27. Kumar Nagi B et al. Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer. *J Clin Trials.* 2014;4:180.
28. Chen YT et al. Over-diagnosis in Lung Cancer Screening using the MSKC-LCSP Data. *J Biomet Biostat.* 2014;5:201.
29. Gironés R. Communication of Diagnosis in Elderly Lung Cancer Patients: Who is Informed, What Information is Given and What Patients Know and Want to Know. *J Palliat Care Med.* 2014;4:184.
30. Nehls W et al. Communication Skills Training Significantly Improves Lung Cancer Patient's Understanding. *J Palliat Care Med.* 2014;4:182.
31. Vasic N et al. Amiodarone-Induced Pulmonary Toxicity Mimicking Metastatic Lung Disease: Case Report. *J Pharmacovigilance.* 2014;2:137.
32. Stone A et al. c-Met: A Potential Target for Current Non-Small-Cell Lung Cancer Therapeutics. *Chemotherapy.* 2014;3:136.
33. Marx G et al. Understanding the Needs and Perspectives of Patients with Incurable Pulmonary Disease at the End of Life and their Relatives: Protocol of a Qualitative Longitudinal Study. *J Palliat Care Med.* 2014;4:177.
34. Monirul Islam KM et al. Developing a Web-Based, Patient-Centered Data Collection and Management Approach for a Multi-Center Lung Cancer Study. *J Integr Oncol.* 2014;3:121.
35. Khan DR. The use of Nanocarriers for Drug Delivery in Cancer Therapy. *J Cancer Sci Ther.* 2010; 2:058-062.
36. Nagai N et al. Effects of Ophthalmic Formulations Containing Cilostazol Nanoparticles on Retinal Vasoconstriction in Rats Injected with Endothelin-1. *Pharm Anal Acta.* 2015;6:354.
37. Danza A et al. A New Example of Nanotechnology Applied to Minimally Processed Fruit: The Case of Fresh-Cut Melon. *J Food Process Technol.* 2015;6:439.
38. Sujata Sirsat A and Jack Neal A. Titanium Dioxide Nanoparticles as an Environmental Sanitizing Agent. *J Microb Biochem Technol.* 2015;7:061-064.
39. Danza A et al. A New Example of Nanotechnology Applied to Minimally Processed Fruit: The Case of Fresh-Cut Melon. *J Food Process Technol.* 2015;6:439.
40. Yadav SK. Nanotechnology: A Spark to the Use of Plant Origin Bioactive Compounds in Therapeutics. *Single Cell Biol.* 2015;4:108.
41. Nikalje AP. Nanotechnology and its Applications in Medicine. *Med chem.* 2015;5:081-089.

42. Matilda A et al. A Review on Ophthalmology using Nanotechnology. J Nanomed Nanotechnol. 2015;6:272.
43. Hungund BS et al. Comparative Evaluation of Antibacterial Activity of Silver Nanoparticles Biosynthesized Using Fruit Juices. J Nanomed Nanotechnol. 2015;6:271.
44. Ramdani L et al. Multifunctional Curcumin-Nanocarriers Based on Host-Guest Interactions for Alzheimer Disease Diagnostic. J Nanomed Nanotechnol. 2015;6:270.
45. Nia Y et al. Determination of Ti from TiO₂ Nanoparticles in Biological Materials by Different ICP-MS Instruments: Method Validation and Applications. J Nanomed Nanotechnol. 2015;6:269.
46. Le TTD et al. Novel Anti-HER2 ScFv Targeted-Docetaxel Nanoparticles in Therapy of HER2 Overexpressed Cancer. J Nanomed Nanotechnol. 2015;6:267.
47. Omprakash V and Sharada S. Green Synthesis and Characterization of Silver Nanoparticles and Evaluation of their Antibacterial Activity using Elettaria Cardamom Seeds. J Nanomed Nanotechnol. 2015;6:266.